In the last newsletter, we announced the formation of a new program at NIDA and it’s now time for a more formal introduction to The NIDA Office of Research Training, Diversity, and Disparities (ORTDD). The work and mission of this office isn’t necessarily new to NIDA, but rather it’s an organizational union between NIDA’s Office of Research Training and NIDA’s Office of Diversity and Health Disparities. The ORTDD is committed to providing research training opportunities across the early-career pipeline to ensure that a cutting-edge diverse research workforce is available and prepared to advance substance use and addiction science.
Within the ORTDD, there are two offices: The Office of Research Training and Career Development, and The Office of Diversity and Health Disparities. The Office of Research Training and Career Development provides research training workshops and funding opportunities to promising scientists across the career pipeline to meet the Nation’s need for substance use and addiction research. NIDA’s research training portfolio includes research in basic, clinical, and translational sciences. The Office of Diversity and Health Disparities supports a vigorous health disparities research program across the NIDA research divisions and offers programs to help undergraduate and graduate students, postdoctoral fellows, and early-stage investigators from underrepresented backgrounds launch their independent research careers. NIDA aims to enhance the representation of underrepresented scientists in the biomedical research workforce through outreach, educational, and research training initiatives and funding opportunities. Combing these offices into one joint office will provide for increase collaborations and better use of resources and training across NIDA and the extramural research community. Please see the new NIDA ORTDD website for more information.
In addition, we would like to introduce you to the ORTDD Director, Dr. Wilson Compton also the NIDA Deputy Director, and Dr. Albert Avila, Deputy Director of the ORTDD and Director of the Office of Diversity and Health Disparities. Feel free to reach out to them should you have any questions about the new office.
Did You Know?
NIH has reissued many of its Fellowship (F) and Career Development (K) parent announcements to incorporate new, required Forms F usage. The reissued parent announcements include:
- Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) PA-20-248
- Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) PA-20-245
- Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) PA-20-246
- Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) PA-20-242
- Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) PA-20-203
- Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required) PA-20-202
- Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required) PA-20-201
- Notice of Requirement for Electronic Submission of all Administrative Supplements: NOT-OD-20-128
Effective immediately, NIH will begin accepting administrative supplement applications for multi-project awards electronically. Since the administrative supplement applies to the parent award as a whole, the single-project application form package used for research grants and cooperative agreements will be used for these submissions (e.g., Competition ID= “FORMS-F-ADMINSUPP-RESEARCH.”)
Effective July 25, 2020, the streamlined submission method through the eRA Commons will be discontinued and replaced with the option to initiate the administrative supplement application within eRA Commons and leverage technology available in NIH ASSIST to complete submission. All supplement applications to existing single and multi-project awards must be submitted electronically through Grants.gov using NIH ASSIST, Grants.gov Workspace, or institutional system-to-system (S2S) solutions.
- Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic: NOT-OD-20-122
The NIH is committed to supporting the biomedical research enterprise as the nation implements the President's Guidelines for Re-Opening America Again. This Notice provides guidance for investigators and institutions preparing NIH grant applications for the May 2021 Council round, beginning with applications submitted for the September 25, 2020 due date.
NIH grant applications should NOT include contingency plans that would outline steps needed to recover from temporary, emergency situations, or institutional return-to-the-workplace plans, resulting from the COVID-19 pandemic.
Contingency plans will not be considered in peer review but, if needed, COVID-19 contingency plans will be requested and carefully considered by NIH staff before funding.
To keep abreast of NIH Covid-19 policies, programs and funding opportunities, visit Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding resource page: https://grants.nih.gov/policy/natural-disasters/corona-virus.htm
- Request for Information (RFI): Enhancing Rigor, Transparency, and Translatability to Improve Biomedical Research Involving Animal Models: NOT-OD-20-130
This Notice is a Request for Information (RFI) inviting comments and suggestions on enhancing scientific rigor in biomedical research involving animal models. It is important to read this entire RFI notice to ensure an adequate response is prepared and to have a full understanding of how your response will be utilized. Responses should be submitted by July 31 electronically on the submission website: https://grants.nih.gov/grants/rfi/rfi.cfm?ID=108.
- NIH Summary Statement Available to the Signing Officials (SO) through the eRA Commons:NOT-OD-20-126
To facilitate award management and communications with applicant organizations via Authorized Organization Representatives (AORs), NIH has modified the system of records by adding a new routine use to clarify that information may be shared with applicant organizations.
Effective June 24, 2020, the overall impact score and the NIH Summary Statement will be made available in the eRA Commons to the Authorized Organization Representatives (AORs) of the applicant organization with the Signing Official (SO) user role in the eRA Commons.
- Reminder of Upcoming FORMS-F and Inclusion Across the Lifespan Requirements for NIH Applicants and Recipients Submitting Post-Submission Updates Using the Human Subjects System (HSS):NOT-OD-20-125 Key FORMS-F Changes to the PHS Human Subjects and Clinical Trials Information Form
As of June 13, all applicants and recipients submitting post-submission updates in the Human Subjects System (HSS) will use the FORMS-F PHS Human Subjects and Clinical Trials Information Form for the submission. All records with a status of “Work in Progress” or “Ready for Submission” will include the FORMS-F fields and must meet the corresponding requirements as of this date. All records with a status of “Ready for Submission” will be changed to “Work in Progress” on June 13.
- Guidance Regarding Change in Status, Including Absence of PD/PI and Other Key Personnel Named in the Notice of Award: NOT-OD-20-124
The purpose of this notice is to clarify NIH expectations regarding change in status, including absence of Program Director / Principal Investigator (PD/PI) and other Key Personnel named in the Notice of Award (NoA) of NIH grants, as well as change in recipient institution. NIH expects that funded biomedical and behavioral research occurs within an environment that is safe, healthful, and conducive to high-quality work.
- Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: NOT-OD-20-123
The NIH, AHRQ, and NIOSH understand that the emergency declaration related to Coronavirus Disease 2019 (COVID-19) will adversely affect the ability of many applicants to generate preliminary data in time for their grant applications submitted for the current due dates (for January 2021 Council beginning with applications submitted for the May 25, 2020 due date). However, with implementation of the President's Guidelines for Re-Opening America Again, NIH, AHRQ, and NIOSH anticipate that many investigators may be able to generate preliminary data for those applications before peer review. Therefore, this Notice provides an exception to the NIH/AHRQ/NIOSH policy for post-submission materials (NOT-OD-19-083).
For applications submitted for the January 2021 council (beginning with applications submitted for the May 25, 2020 due date for Fall 2020 review meetings), the NIH, AHRQ, and NIOSH will accept a one-page update with preliminary data as post-submission materials for applications submitted under all activity codes, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application. One page of preliminary data will be accepted for single component applications or for each component of a multi-component application.
For a full list of training, fellowship, career development, and research education funding opportunities, including parent announcements, please see the NIH Research Training and Career Development webpage.
- Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed) PAR-20-076
- Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (F31-Diversity) PA-20-251
- NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00) RFA-NS-19-011
- Drug Abuse Dissertation Research (R36) PA-20-208
- Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed) PAR-19-343
- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Clinical Trial Required) RFA-19-044
- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed) RFA-19-043
- Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed) RFA-OD-20-009
- Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required) RFA-OD-20-010
- Notice of Intent to Publish a Funding Opportunity Announcement for "BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) NOT-MH-20-062
- Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed) RFA-OD-20-008
- Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required) RFA-OD-20-011
- Notice of NIDA Participation in PAR-20-039, Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed) NOT-DA-20-025
- Notice of NIDA Participation in PAR-20-040, Support of Competitive Research (SCORE) Pilot Project Award (SC2 Clinical Trial Not Allowed) NOT-DA-20-026
- Notice of Special Interest: Administrative Supplements for Research on Sex/Gender Influences (Admin Supp Clinical Trial Optional) NOT-OD-20-049
- Notice of Special Interest for Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional) NOT-OD-20-032
Applications in response to this NOSI must be submitted using PA-18-591
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)-PAR-20-249
- NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) PAR-19-258
- Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed) PAR-19-246
- Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed) PAR-19-207
- Summer Research Education Experience Program (R25 Clinical Trial Not Allowed) PAR-19-197
- Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) PA-20-222
- Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations: NOT-OD-20-121
- Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations: NOT-OD-20-120
- Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional) PAR-20-125
Please visit www.drugabuse.gov/international/upcoming-meetings to find information on scientific meetings, which have relevance to substance use/substance use disorder research. Please note, many upcoming meetings and events may be canceled or postponed due to the COVID-19 public health emergency. We encourage you to check the respective meeting websites for updates on their official status.